

5 December 2025

ASX Announcement

US Patent Granted for Galidesivir Program Extends Patent Estate

- **US Patent Number 12,472,197 granted by the US Patent and Trademark Office for the use of Galidesivir in the treatment of the SARS-CoV-2 'Covid-19' virus**
- **Provides long-term patent protection through July 2042 for the use of Galidesivir as a treatment option for Covid-19**
- **Further strengthens the IP portfolio of the Galidesivir program, which already includes several issued patents with additional patent applications pending**
- **Supports the use of Galidesivir as a broad-acting antiviral molecule, following recent FDA confirmation of Galidesivir's eligibility under the Animal Rule pathway for its lead indication as a countermeasure the Marburg virus**

MELBOURNE Australia, 5 December 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise it has been granted by the US Patent and Trademark Office ('USPTO') US Patent Number 12,472,197 for use of Galidesivir in the treatment of SARS-CoV-2 ('Covid-19') infections.

As part of the successful acquisition of the Galidesivir program in July 2025 (refer ASX Announcement 31 July 2025), Island acquired the rights to a robust patent portfolio comprising both issued patents and pending patent applications, to provide global patent protection for the Galidesivir program as a treatment option for a variety of different viruses.

USPTO patent number 12,472,197, titled "Methods, Compositions, and Dosing Regimens for Treatment of SARSCoV-2 Infections" provides Island with US patent protection until July 18, 2042, to pursue treatment options for Covid-19 infections using Galidesivir.

Patent approval for the use of Galidesivir as a Covid-19 treatment further supports its potential application as a broad-acting antiviral molecule, complementing Island's near-term focus to advance the regulatory pathway for its lead indication as a countermeasure to the Marburg virus.

Management commentary:

CEO and Managing Director, Dr David Foster said: "Issuance of this patent is another pleasing development for the Galidesivir program. As well as supporting the program's potential as a broad-acting antiviral, it also provides Island with long-term patent protection through 2042 for the application of Galidesivir as a Covid-19 treatment. Access to an extensive patent portfolio was one of several key benefits identified by Island prior to its strategic acquisition of the asset. We are pleased to have extended our IP footprint with this approval, and are now working hard to deliver on our near-term development strategy for the Galidesivir program."



- Ends -

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.